BioCentury
ARTICLE | Company News

Vitesse launches first newco Thunderbolt

May 26, 2016 12:08 AM UTC

Vitesse Biologics LLC (South San Francisco, Calif.) launched virtual newco Thunderbolt Pharma Inc. (South San Francisco, Calif.), which will house a preclinical dual antagonist program targeting BLyS (BAFF) and tumor necrosis factor (TNF) ligand superfamily member 13 ( TNFSF13; APRIL) to treat B cell-mediated disorders including systemic lupus erythematosus (SLE).

Thunderbolt acquired the program from Astellas Pharma Inc. (Tokyo:4503) for undisclosed terms. Velocity SVP of Business Development Stuart Sedlack said Astellas received an undisclosed equity stake in Thunderbolt. ...